Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Charalambos D. Partidos, Joanna Paykel, James Weger, Erin M. Borland, Ann M. Powers, Robert Seymour, Scott Weaver, Dan T. Stinchcomb, Jorge E. Osorio

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

Original languageEnglish (US)
Pages (from-to)4638-4643
Number of pages6
JournalVaccine
Volume30
Issue number31
DOIs
StatePublished - Jun 29 2012

Fingerprint

Chikungunya virus
cross immunity
Synthetic Vaccines
Immunity
vaccines
Viruses
viruses
Vaccines
Alphavirus Infections
Alphavirus
Virus Diseases
Neutralizing Antibodies
Culicidae
neutralizing antibodies
Antibody Formation
Disease Outbreaks
antiserum
Immune Sera
animal models
antibodies

Keywords

  • A129 mice
  • Chikungunya virus (CHIKV)
  • Interferon (IFN)
  • Maternal-fetal immunity
  • O'nyong-nyong virus (ONNV)

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Partidos, C. D., Paykel, J., Weger, J., Borland, E. M., Powers, A. M., Seymour, R., ... Osorio, J. E. (2012). Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine, 30(31), 4638-4643. https://doi.org/10.1016/j.vaccine.2012.04.099

Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. / Partidos, Charalambos D.; Paykel, Joanna; Weger, James; Borland, Erin M.; Powers, Ann M.; Seymour, Robert; Weaver, Scott; Stinchcomb, Dan T.; Osorio, Jorge E.

In: Vaccine, Vol. 30, No. 31, 29.06.2012, p. 4638-4643.

Research output: Contribution to journalArticle

Partidos, CD, Paykel, J, Weger, J, Borland, EM, Powers, AM, Seymour, R, Weaver, S, Stinchcomb, DT & Osorio, JE 2012, 'Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine', Vaccine, vol. 30, no. 31, pp. 4638-4643. https://doi.org/10.1016/j.vaccine.2012.04.099
Partidos, Charalambos D. ; Paykel, Joanna ; Weger, James ; Borland, Erin M. ; Powers, Ann M. ; Seymour, Robert ; Weaver, Scott ; Stinchcomb, Dan T. ; Osorio, Jorge E. / Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. In: Vaccine. 2012 ; Vol. 30, No. 31. pp. 4638-4643.
@article{37b3163f93b4449482e639d34a7529a7,
title = "Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine",
abstract = "Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.",
keywords = "A129 mice, Chikungunya virus (CHIKV), Interferon (IFN), Maternal-fetal immunity, O'nyong-nyong virus (ONNV)",
author = "Partidos, {Charalambos D.} and Joanna Paykel and James Weger and Borland, {Erin M.} and Powers, {Ann M.} and Robert Seymour and Scott Weaver and Stinchcomb, {Dan T.} and Osorio, {Jorge E.}",
year = "2012",
month = "6",
day = "29",
doi = "10.1016/j.vaccine.2012.04.099",
language = "English (US)",
volume = "30",
pages = "4638--4643",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "31",

}

TY - JOUR

T1 - Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

AU - Partidos, Charalambos D.

AU - Paykel, Joanna

AU - Weger, James

AU - Borland, Erin M.

AU - Powers, Ann M.

AU - Seymour, Robert

AU - Weaver, Scott

AU - Stinchcomb, Dan T.

AU - Osorio, Jorge E.

PY - 2012/6/29

Y1 - 2012/6/29

N2 - Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

AB - Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

KW - A129 mice

KW - Chikungunya virus (CHIKV)

KW - Interferon (IFN)

KW - Maternal-fetal immunity

KW - O'nyong-nyong virus (ONNV)

UR - http://www.scopus.com/inward/record.url?scp=84861977697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861977697&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.04.099

DO - 10.1016/j.vaccine.2012.04.099

M3 - Article

VL - 30

SP - 4638

EP - 4643

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 31

ER -